Why is the legend of the highest position local professional manager in a multinational company?

  none="shifuMouseDownCard('shifu_c_029')" label="Copyright Reserved by PLAYHUDONG." style="margin: 1em 0px; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border: 0px; box-sizing: border-box !im portant; word-wrap: break-word !im Four months ago, everyone congratulated Wang Lei, then president of China, on his promotion to President of AstraZeneca Asia Pacific and China Who would like to four months later, Wang Lei was officially appointed president of the international department and continues to report directly to CEO Pascal Jo Feng will be the general manager of China and report to Wang Lei AstraZeneca International Department is responsible for the Asia Pacific, Middle East, Russia, Africa, central and South America of AstraZeneca The booming BRICs are all under the jurisdiction of the international ministry Wang Lei's promotion has made him the top local professional manager in a multinational company What happened in the past four months that made Wang Lei leap here like a rocket? Xiaobian will check it for you   none="shifuMouseDownStyle('shifu_t_026')" style="margin: 0px; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border: none; text-align: center; box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> 1 Teresa went on the market quickly On March 24, AstraZeneca's Teresa set the fastest record in the history of China from approval to market for imported drugs The clinical application was submitted in China on September 3, 2016, and was approved for listing in March 2017 The whole process was only seven months, only 15 months later than the listing in the United States Two weeks after CFDA was approved, Teresa officially went public in China, far exceeding AstraZeneca's expectations for China Wang Lei's preparations can be seen Teresa is the first batch of third-generation lung cancer targeting drugs approved for marketing in China, which will bring a major breakthrough in small cell lung cancer and other diseases in China It's because of the clinical importance of Teresa that Wang Lei is determined to promote the listing of Teresa in China None = "shifumousedownstyle ('shifu_t_ ')" style = "margin: 0px; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font family:' hiragino sans GB ',' Microsoft YaHei ', Arial, sans serif; font size: 16px; line height: 25.6px; Border: none; text align: Center; box sizing: border box! Im assistant; word wrap: break word! Im assistant; "> 2.6 billion US dollars in China has become the strongest support On February 2, AstraZeneca released its 2016 financial report With a growth rate of $2.6 billion and 10%, China has become the only region with double-digit growth in AstraZeneca's global market Sales in mature markets are growing negatively, while emerging markets such as China are climbing steadily At this time, Wang Lei was appointed president of the International Department, demonstrating AstraZeneca's ambition in emerging markets In fact, in the four months when Wang Lei was president of the Asia Pacific region and visited various emerging Asian markets, he has made important changes in many Asian markets (such as India, Australia, etc.) AK word! Im assistant; "> 3 cross border Establish the Foursquare Internet of things platform AstraZeneca, Ericsson, Jiangsu Mobile, and Wuxi Municipal government joined forces to launch the pharmaceutical Internet of things platform in Wuxi, Jiangsu Province The integrated medical and health platform has always been the development path explored by major pharmaceutical enterprises Wang Lei's solution is to bring information, equipment and services of health care to everyone in combination with local government, communication operators and other resources This cross-border cooperation not only promotes AstraZeneca's rapid development in China, but also benefits many enterprises Interestingly, AstraZeneca and Ericsson's global chairman happen to be the same person With the supporters of the above three major breakthroughs, Wang Lei's pace towards becoming an international market leader is not stable Wang Lei and others are the "atypical" leaders model that this era expects     none="shifuMouseDownStyle('shifu_t_027')" style="margin: 0px; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border: none; text-align: center; box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> leaders in the cross-border and innovative pharmaceutical industry generally have a professional background in medicine However, Wang Lei's background is "non medicine, non medicine" Before becoming a professional manager, Wang Lei once worked as a tour guide, translator, etc The background of multi industry makes Wang Lei always be able to jump out of the frame of thinking, connect all kinds of resources and open up a new path The Internet of things of quartet is a vivid example, and there are many such examples in his career, such as the market praise of pumik Lingshu through 3D (drug, device, digital) innovation Wang Lei's success has proved the importance of innovative business model in the Chinese market, and the transformation and development of the pharmaceutical market also need such leadership to bring about model change     none="shifuMouseDownStyle('shifu_t_027')" style="margin: 0px; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border: none; text-align: center; box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> the leadership brand is posted on the office door of Wang Lei with his own wechat QR code Anyone can scan and add him as a friend, and Wang Lei will surely pass Such a busy person will also take time to make personal communication with people inside and outside the company Such a form of communication is a good embodiment of Wang Lei's people-friendly leadership brand Graduated from CEIBS, he believes that a flat organization can stimulate employees' initiative and innovation ability   none="shifuMouseDownCard('shifu_c_029')" label="Copyright Reserved by PLAYHUDONG." style="margin: 1em 0px; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border: 0px; box-sizing: border-box !im portant; word-wrap: break-word !im Assistant; "> after Wang Lei, the new general manager in China, is promoted, the position of general manager in China will be assigned to Jo Feng, who will report directly to Wang Lei Jo Feng joined AstraZeneca in 2003 From 2003 to 2015, Jo held several important management positions, including Vice President of cardiovascular business Her achievements at AstraZeneca are widely recognized by businesses Since 2015, Jo has been sent to the United States to take charge of the strategy formulation of the whole ina TA This role has made AstraZeneca see Jo's outstanding leadership in innovative business model and entrepreneurship As the general manager of China, Jo will be responsible for all market, sales and business operations in China except for cancer Wang Lei will continue to be in charge of cancer At the same time, AstraZeneca also announced that ISKRA REIC, the current president of Russia, will become president of Europe As can be seen from these major appointments, Pascal, CEO of AstraZeneca, attaches great importance to the experience of developing countries I hope to use the innovation of China and Russia / Eastern Europe market to bring some different ideas and ideas to the mature market.